Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02762513 · ClinicalTrials.gov registry record · Phase 2
Expansion Trial for Axitinib In Head And Neck Cancer
A Phase 2 study, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
NCT02762513 is a Phase 2 study that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 29 participants.
The verdict
NCT02762513, a Phase 2 study, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
Study Summary
This study will be a prospective, single-institution, single-arm phase II study of Axitinib in patients with unresectable recurrent and metastatic head and neck squamous cell carcinoma. The subjects will be started on treatment with 5 mg of Axitinib twice a day continuously, with subsequent dose escalation to 7 mg and then 10 mg twice a day in the absence of grade 2 or worse toxicities. This will be followed by clinical and/or radiologic response assessment after 8 weeks and subsequently every 2 months until disease progression or intolerable toxicity.
Interventions
- DRUG Axitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2016-08-30 |
| Est. Completion | 2020-04-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02762513
The ClinicalTrials.gov registry entry for NCT02762513 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Axitinib is the first listed.
NCT02762513 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02762513 about?
NCT02762513 is a clinical study titled "Expansion Trial for Axitinib In Head And Neck Cancer". This study will be a prospective, single-institution, single-arm phase II study of Axitinib in patients with unresectable recurrent and metastatic head and neck squamous cell carcinoma. The subjects will be started on treatment with 5 mg of Axitinib twice a day continuously, with subsequent dose esc...
What is the current status of trial NCT02762513?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2016-08-30. Estimated completion is 2020-04-09.
What interventions are being tested in trial NCT02762513?
The interventions under investigation include: Axitinib (DRUG).
Who is sponsoring clinical trial NCT02762513?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.